Tetrazepam

Tetrazepam

Clinical data
AHFS/Drugs.com	International Drug Names
Routes of administration	Oral
ATC code	M03BX07 (WHO)
Legal status
Legal status	BR: Class B1 (Psychoactive drugs)[1] CA: Schedule IV DE: Prescription only (Anlage III for higher doses) UK: Class C US: Schedule IV
Pharmacokinetic data
Elimination half-life	3–26 hours
Identifiers
IUPAC name 7-chloro-5-(cyclohexen-1-yl)-1-methyl-3H-1,4-benzodiazepin-2-one
CAS Number	10379-14-3 Y
PubChem CID	25215
ChemSpider	23551 Y
UNII	FO92091VP8
KEGG	D07277 Y
CompTox Dashboard (EPA)	DTXSID00146058
ECHA InfoCard	100.030.749
Chemical and physical data
Formula	C16H17ClN2O
Molar mass	288.77 g·mol−1
3D model (JSmol)	Interactive image
SMILES CN1C(=O)CN=C(C2=C1C=CC(=C2)Cl)C3=CCCCC3
InChI InChI=1S/C16H17ClN2O/c1-19-14-8-7-12(17)9-13(14)16(18-10-15(19)20)11-5-3-2-4-6-11/h5,7-9H,2-4,6,10H2,1H3 Y Key:IQWYAQCHYZHJOS-UHFFFAOYSA-N Y
(verify)

Tetrazepam^[2] (is marketed under the following brand names, Clinoxan, Epsipam, Myolastan, Musaril, Relaxam and Spasmorelax) is a benzodiazepine derivative with anticonvulsant, anxiolytic, muscle relaxant and slightly hypnotic properties. It was formerly used mainly in Austria, France, Belgium, Germany and Spain to treat muscle spasm, anxiety disorders such as panic attacks, or more rarely to treat depression, premenstrual syndrome or agoraphobia. Tetrazepam has relatively little sedative effect at low doses while still producing useful muscle relaxation and anxiety relief. The Co-ordination Group for Mutual Recognition and Decentralised Procedures-Human (CMD(h)) endorsed the Pharmacovigilance Risk Assessment Committee (PRAC) recommendation to suspend the marketing authorisations of tetrazepam-containing medicines across the European Union (EU) in April 2013.^[3] The European Commission has confirmed the suspension of the marketing authorisations for Tetrazepam in Europe because of cutaneous toxicity, effective from the 1 August 2013.^[4]

Delayed type 4 allergic hypersensitivity reactions including maculopapular exanthema, erythematous rash, urticarial eruption, erythema multiforme, photodermatitis, eczema and Stevens–Johnson syndrome can occasionally occur as a result of tetrazepam exposure. These hypersensitivity reactions to tetrazepam share no cross-reactivity with other benzodiazepines.^[5]